<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00546156</url>
  </required_header>
  <id_info>
    <org_study_id>07-130</org_study_id>
    <nct_id>NCT00546156</nct_id>
  </id_info>
  <brief_title>Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer</brief_title>
  <official_title>A Phase II Study of Preoperative Dose-dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel (T) With Bevacizumab in ER+ and/or PR+, HER2-negative Operable Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ian E. Krop, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>New Hampshire Oncology-Hematology PA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dose dense chemotherapy, which is the term for Adriamycin and Cyclophosphamide (AC) followed
      by Taxol chemotherapy given every two weeks, is the standard chemotherapy for the treatment
      of ER+ or PR+ breast cancer. In this trial, the standard chemotherapy is being combined with
      bevacizumab. Bevacizumab is an antibody which works differently from the way other
      chemotherapy drugs work. Bevacizumab slows or stops cell growth in cancerous tumors by
      decreasing the blood supply to the tumors by binding to a substance found on cancer cells
      called VEGF (vascular endothelial growth factor). Bevacizumab is approved by the FDA for the
      treatment of colorectal cancer and lung cancer. However, it is not approved for the treatment
      of breast cancer. Another goal of this research is to determine whether we can develop a way
      to identify tumors that will respond well to this study treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  To prepare for the surgery that will occur at the end of the study treatment, a small
           &quot;clip&quot; will be placed into the tumor area so that the surgeon can locate the site of the
           tumor at the time of surgery. This is a standard procedure for breast cancer.

        -  During the clip placement, a needle will be inserted into the tumor to measure
           interstitial fluid pressure (IFP measurement). IFP is done for research purposes to help
           understand how the tumor responds to the study treatment.

        -  Study treatment will begin with one dose of bevacizumab alone, followed two weeks later
           by chemotherapy and bevacizumab in eight two-week cycles. The study treatment will be
           given intravenously in the clinic.

        -  After the first dose of bevacizumab and prior to starting chemotherapy, a needle biopsy
           of the breast tumor will be performed for research purposes. A second measurement of IFP
           will also be done at this time.

        -  During the treatment period, tests and procedures will be performed at specified
           intervals and include the following: research MRI, physical exams, blood tests, urine
           tests, EKG, and MUGA or ECHO.

        -  Surgery to remove the tumor will occur no less than four weeks after the last dose of
           Paclitaxel.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic Complete Response Rate After Preoperative Therapy in This Patient Population.</measure>
    <time_frame>3 Years</time_frame>
    <description>Pathological Complete response is defined as complete disappearance of invasive tumor in the breast at the time of surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease in Interstitial Fluid Pressure.</measure>
    <time_frame>3 years</time_frame>
    <description>To determine if bevacizumab monotherapy results in a decrease in interstitial fluid pressure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>HR+, HER2-</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with Hormone Receptor Positive, HER2 negative Breast Cancer. A single dose of Bevacizumab 10mg/kg, followed two weeks later by Adriamycin60 mg/m2 and Cyclophosphamide 600 mg/m2 with Bevacizumab 10mg/kg every 2 weeks x4, followed by Taxol 175 mg/m2 with Bevacizumab 10 mg/kg every 2 weeks x3, followed by Taxol 175 mg/m2 x1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triple Negative Breast Cancer Cohort</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hormone receptor negative, HER2 negative Cohort. Receive same drug protocol as Arm A.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Standard chemotherapy regimen</description>
    <arm_group_label>HR+, HER2-</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer Cohort</arm_group_label>
    <other_name>Adriamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Standard chemotherapy regimen</description>
    <arm_group_label>HR+, HER2-</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer Cohort</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Standard chemotherapy regimen</description>
    <arm_group_label>HR+, HER2-</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer Cohort</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>One intravenous dose given followed 2 weeks later with standard chemotherapy drugs and bevacizumab given intravenously in 8 two-week cycles.</description>
    <arm_group_label>HR+, HER2-</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer Cohort</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented primary invasive breast cancer by histologic assessment

          -  Tumors must express estrogen (ER) and/or progesterone receptors (PR) by standard
             immunohistochemical methods. Tumors must be negative for HER2. There must be
             sufficient sample for further protocol-specified immunohistochemical analysis

          -  Patients must have high risk ER+ or PR+ breast cancer as defined by criteria listed in
             protocol

          -  18 year of age or older

          -  Performance status of 0 or 1 by ECOG criteria

          -  Use of an effective means of contraception in subjects of childbearing potential

          -  Women of childbearing potential must have a negative serum pregnancy test within 14
             days prior to starting therapy.

          -  Patients taking exogenous sex-steroid hormone treatments for any reason at the time of
             diagnosis must discontinue all hormonal treatments at least 2 weeks prior to
             enrollment

          -  Patients must have preoperative treatment within 60 days of initial diagnosis of
             breast cancer

          -  No other malignancy that requires on-going treatment

          -  Normal organ function as outlined in the protocol

        Exclusion Criteria:

          -  Prior cytotoxic chemotherapy or radiation for the current breast cancer

          -  Patients with inflammatory breast cancer

          -  HER2 positive disease defined as HER2-amplified by FISH or IHC 3+. HER2 2+ must be
             negative by FISH

          -  Known metastatic (Stage IV) disease

          -  Other investigational agents within 4 weeks prior to the start of study treatment

          -  Life expectancy of less than 6 months

          -  Peripheral neuropathy greater than or equal to grade 2

          -  Inadequately controlled hypertension

          -  Any prior history of hypertensive crisis or hypertensive encephalopathy

          -  NYHA grade II or greater congestive heart failure

          -  History of prior myocardial infarction

          -  History of unstable angina within 12 months prior to study enrollment

          -  Any history of stroke or transient ischemic attack at any time

          -  Known CNS disease

          -  Significant vascular disease

          -  Symptomatic peripheral vascular disease

          -  Evidence of significant bleeding within 6 months of study; any serious non-healing
             wound, skin ulcers, or bone fracture; any abdominal fistula, gastrointestinal
             perforation or intra-abdominal abscess within the past 6 months; any major surgical
             procedure within 28 days prior to randomization or anticipation of need for major
             surgery during course of study.

          -  Known HIV positive

          -  Unwilling to undergo pretreatment biopsy and consent to acquisition of archival tissue

          -  Pregnant of lactating

          -  Known hypersensitivity to any component of bevacizumab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian Krop, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber at Faulkner Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Hampshire Oncology-Hematology PA</name>
      <address>
        <city>Hooksett</city>
        <state>New Hampshire</state>
        <zip>03106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2007</study_first_submitted>
  <study_first_submitted_qc>October 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2007</study_first_posted>
  <results_first_submitted>March 22, 2013</results_first_submitted>
  <results_first_submitted_qc>March 22, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 10, 2013</results_first_posted>
  <last_update_submitted>March 22, 2013</last_update_submitted>
  <last_update_submitted_qc>March 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Ian E. Krop, MD, PhD</investigator_full_name>
    <investigator_title>Medical Oncologist</investigator_title>
  </responsible_party>
  <keyword>ER positive</keyword>
  <keyword>PR positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study was activated on 10/17/2007 and Closed to accrual on 7/1/2011.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>HR+, HER2-</title>
          <description>Patients with Hormone Receptor Positive, HER2 negative Breast Cancer. A single dose of Bevacizumab 10mg/kg, followed two weeks later by Adriamycin60 mg/m2 and Cyclophosphamide 600 mg/m2 with Bevacizumab 10mg/kg every 2 weeks x4, followed by Taxol 175 mg/m2 with Bevacizumab 10 mg/kg every 2 weeks x3, followed by Taxol 175 mg/m2 x1.</description>
        </group>
        <group group_id="P2">
          <title>Triple Negative Breast Cancer Cohort</title>
          <description>Hormone receptor negative, HER2 negative Cohort. Receive same drug protocol as Arm A.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HR+, HER2-</title>
          <description>Patients with Hormone Receptor Positive, HER2 negative Breast Cancer. A single dose of Bevacizumab 10mg/kg, followed two weeks later by Adriamycin60 mg/m2 and Cyclophosphamide 600 mg/m2 with Bevacizumab 10mg/kg every 2 weeks x4, followed by Taxol 175 mg/m2 with Bevacizumab 10 mg/kg every 2 weeks x3, followed by Taxol 175 mg/m2 x1.</description>
        </group>
        <group group_id="B2">
          <title>Triple Negative Breast Cancer Cohort</title>
          <description>Hormone receptor negative, HER2 negative Cohort. Receive same drug protocol as Arm A.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="84"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="104"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.5" lower_limit="24" upper_limit="66"/>
                    <measurement group_id="B2" value="47.5" lower_limit="22" upper_limit="65"/>
                    <measurement group_id="B3" value="47.5" lower_limit="22" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pathologic Complete Response Rate After Preoperative Therapy in This Patient Population.</title>
        <description>Pathological Complete response is defined as complete disappearance of invasive tumor in the breast at the time of surgery</description>
        <time_frame>3 Years</time_frame>
        <population>Participants who met all study eligibility criteria and signed informed consent.</population>
        <group_list>
          <group group_id="O1">
            <title>HR+, HER2-</title>
            <description>Patients with Hormone Receptor Positive, HER2 negative Breast Cancer. A single dose of Bevacizumab 10mg/kg, followed two weeks later by Adriamycin60 mg/m2 and Cyclophosphamide 600 mg/m2 with Bevacizumab 10mg/kg every 2 weeks x4, followed by Taxol 175 mg/m2 with Bevacizumab 10 mg/kg every 2 weeks x3, followed by Taxol 175 mg/m2 x1.</description>
          </group>
          <group group_id="O2">
            <title>Triple Negative Breast Cancer Cohort</title>
            <description>Hormone receptor negative, HER2 negative Cohort. Receive same drug protocol as Arm A.</description>
          </group>
        </group_list>
        <measure>
          <title>Pathologic Complete Response Rate After Preoperative Therapy in This Patient Population.</title>
          <description>Pathological Complete response is defined as complete disappearance of invasive tumor in the breast at the time of surgery</description>
          <population>Participants who met all study eligibility criteria and signed informed consent.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Decrease in Interstitial Fluid Pressure.</title>
        <description>To determine if bevacizumab monotherapy results in a decrease in interstitial fluid pressure</description>
        <time_frame>3 years</time_frame>
        <population>This represents the number of patients with paired IFP measurements from day 0 and day 14</population>
        <group_list>
          <group group_id="O1">
            <title>HR+, HER2-</title>
            <description>Patients with Hormone Receptor Positive, HER2 negative Breast Cancer. A single dose of Bevacizumab 10mg/kg, followed two weeks later by Adriamycin60 mg/m2 and Cyclophosphamide 600 mg/m2 with Bevacizumab 10mg/kg every 2 weeks x4, followed by Taxol 175 mg/m2 with Bevacizumab 10 mg/kg every 2 weeks x3, followed by Taxol 175 mg/m2 x1.</description>
          </group>
          <group group_id="O2">
            <title>Triple Negative Breast Cancer Cohort</title>
            <description>Hormone receptor negative, HER2 negative Cohort. Receive same drug protocol as Arm A.</description>
          </group>
        </group_list>
        <measure>
          <title>Decrease in Interstitial Fluid Pressure.</title>
          <description>To determine if bevacizumab monotherapy results in a decrease in interstitial fluid pressure</description>
          <population>This represents the number of patients with paired IFP measurements from day 0 and day 14</population>
          <units>mm Hg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70" lower_limit="0.37" upper_limit="1.32"/>
                    <measurement group_id="O2" value="1.04" lower_limit="0.69" upper_limit="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>All Study Participants</title>
          <description>Patients with HER2 negative Breast Cancer. A single dose of Bevacizumab 10mg/kg, followed two weeks later by Adriamycin60 mg/m2 and Cyclophosphamide 600 mg/m2 with Bevacizumab 10mg/kg every 2 weeks x4, followed by Taxol 175 mg/m2 with Bevacizumab 10 mg/kg every 2 weeks x3, followed by Taxol 175 mg/m2 x1.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>paranasal sinus reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>febrile neutropenia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Hematologic-other</sub_title>
                <counts group_id="E1" events="194" subjects_affected="38" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="387" subjects_affected="86" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" events="39" subjects_affected="24" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="182" subjects_affected="56" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Nose-hemorrhage</sub_title>
                <counts group_id="E1" events="68" subjects_affected="33" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="54" subjects_affected="30" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="29" subjects_affected="15" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="304" subjects_affected="79" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" events="32" subjects_affected="20" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdomen-pain</sub_title>
                <counts group_id="E1" events="16" subjects_affected="10" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="40" subjects_affected="20" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="89" subjects_affected="47" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="65" subjects_affected="34" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="45" subjects_affected="21" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>GI-other</sub_title>
                <counts group_id="E1" events="34" subjects_affected="20" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" events="29" subjects_affected="12" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="197" subjects_affected="76" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="29" subjects_affected="25" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional-other</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="367" subjects_affected="91" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>fever w/o neutropenia</sub_title>
                <counts group_id="E1" events="35" subjects_affected="22" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="35" subjects_affected="19" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Oral cavity-pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Pain-other</sub_title>
                <counts group_id="E1" events="41" subjects_affected="27" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Taste disturbance</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Voice changes/dysarthria</sub_title>
                <counts group_id="E1" events="32" subjects_affected="15" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="17" subjects_affected="7" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>ALT-SGPT</sub_title>
                <counts group_id="E1" events="84" subjects_affected="48" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>AST-SGOT</sub_title>
                <counts group_id="E1" events="120" subjects_affected="48" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection-other</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Muco/stomatitis (symptom) oral cavity</sub_title>
                <counts group_id="E1" events="49" subjects_affected="23" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Muco/stomatitis by exam-oral cavity</sub_title>
                <counts group_id="E1" events="28" subjects_affected="18" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alkaline Phosphatase</sub_title>
                <counts group_id="E1" events="87" subjects_affected="36" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Bicarbonate</sub_title>
                <counts group_id="E1" events="41" subjects_affected="19" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="7" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="13" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="11" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Metabolic/laboratory-other</sub_title>
                <counts group_id="E1" events="123" subjects_affected="37" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back-pain</sub_title>
                <counts group_id="E1" events="27" subjects_affected="22" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Bone-pain</sub_title>
                <counts group_id="E1" events="27" subjects_affected="16" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Extremity-limb-pain</sub_title>
                <counts group_id="E1" events="18" subjects_affected="13" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Joint-pain</sub_title>
                <counts group_id="E1" events="60" subjects_affected="31" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Muscle-pain</sub_title>
                <counts group_id="E1" events="96" subjects_affected="53" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Throat/pharynx/larynx-pain</sub_title>
                <counts group_id="E1" events="44" subjects_affected="30" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="129" subjects_affected="57" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Neuropathy-motor</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="32" subjects_affected="18" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="115" subjects_affected="34" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="53" subjects_affected="30" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="59" subjects_affected="26" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="47" subjects_affected="21" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut-upper airway</sub_title>
                <counts group_id="E1" events="15" subjects_affected="10" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Pulmonary-Upper Respiratory-other</sub_title>
                <counts group_id="E1" events="36" subjects_affected="19" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="179" subjects_affected="39" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>erythema multiforme</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Hand-foot reaction</sub_title>
                <counts group_id="E1" events="12" subjects_affected="6" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Nail changes</sub_title>
                <counts group_id="E1" events="19" subjects_affected="9" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <counts group_id="E1" events="150" subjects_affected="64" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="36" subjects_affected="25" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="59" subjects_affected="27" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Skin-other</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Ian Krop</name_or_title>
      <organization>Dana-Farber Cancer Institute</organization>
      <phone>617-632-2335</phone>
      <email>ian.krop@dfci.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

